Obesity Action Coalition (OAC) Releases Statement on Food and Drug Administration’s (FDA) Update to Wegovy® Label
in OAC Blog, OAC Newsroom on March 8, 2024

The anti-obesity medication Wegovy® has been approved by the US Food and Drug Administration (FDA) for cardiovascular risk reduction in people with overweight or obesity and an established cardiovascular disease. The approval is based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy® statistically significantly reduced the risk of major adverse cardiovascular events. Obesity
Read Article